References

Brandes et al. “N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.” Cancer Chemother Pharmacol. 2000;45(4):298-304.
Liu & Powles, “Cannabinoids: Do they have a role in cancer therapy?” Lett Drug Disc Des. 2006; 3(2): 76-87(7).
Mechoulam et al., “Cannabidiol—recent advances.” Chem Biodividers. 2007 Aug;4(8):1678-92.
Payré et al. “Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism.” Mol Cancer Ther. 2008 Dec;7(12):3707-18.
Liu et al., “Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids.” Curr Clin Pharmacol. 2010 Nov;5(4):281-7.
Zanetti et al., “Effects of Endocannabinoid System Modulation on Cognitive and Emotional Behavior.” Front Behav Neurosci. 2011; 5: 57.
Massi et al., “Cannabidiol as potential anticancer drug.” Br J Clin Pharmacol. 2013 Feb; 75(2): 303–312.
Georges et al. “A tamoxifen derivative, N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine, selectively targets P-glycoprotein-positive multidrug resistant Chinese hamster cells.” Biochem Pharmacol. 2014 Jul 15;90(2):107-14.
Marzo and Piscitelli, “The Endocannabinoid System and its Modulation by Phytocannabinoids”. Neurotherapeutics. 2015 Oct;12(4):692-8. doi: 10.1007/s13311-015-0374-6.
Ladin et al., “Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents.” Front Pharmacol. 2016; 7: 361.
Scott et al., “Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration.” Int J Oncol. 2017 Jul;51(1):369-377.
Śledziński et al., The current state and future perspectives of cannabinoids in cancer biology.” Cancer Med. 2018 Mar; 7(3): 765–775.
Jordà et al., “The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner.” Blood. 2004 Jul 15;104(2):526-34.
Powles et al., “Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway.” Blood. 2005 Feb 1;105(3):1214-21.
McKallip et al., “Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.” Mol Pharmacol. 2006 Sep;70(3):897-908.
Liu et al., “Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids.” Curr Clin Pharmacol. 2010 Nov;5(4):281-7.
Sant et al., “Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.” Blood. 2010 Nov 11;116(19):3724-34.
Smith et al., “Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.” Br J Cancer. 2011 Nov 22;105(11):1684-92
Scott et al., “Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules.” Anticancer Res. 2013 Oct;33(10):4373-80.
Yeshurun et al., “Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.” Biol Blood Marrow Transplant. 2015 Oct;21(10):1770-5.
De Kouchkovsky et al., “Acute myeloid leukemia: a comprehensive review and 2016 update.” Blood Cancer J. 2016 Jul 1;6(7):e441.
Döhner et al., “Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.” Blood. 2017 Jan 26; 129(4): 424–447.
Scott et al., “Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration.” Int J Oncol. 2017 Jul;51(1):369-377.
Burris et al., “Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.” J Clin Oncol. 1997 Jun;15(6):2403-13.
Porta et al., “Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage.” Clin Transl Oncol. 2005 Jun;7(5):189-97.
Fogli et al., “Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism.” FEBS Lett. 2006 Mar 20;580(7):1733-9.
Carracedo et al., “The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells.” Cancer Cell. 2006 Apr;9(4):301-12.
Carracedo et al., “Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.” Cancer Res. 2006 Jul 1;66(13):6748-55.
Michalski et al., “Cannabinoids in pancreatic cancer: Correlation with survival and pain.” Int J Cancer. 2008 Feb 15; 122(4): 742–750.
Donadelli et al., “Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.” Cell Death Dis. 2011 Apr 28;2:e152.
Bosetti et al., “Pancreatic cancer: overview of descriptive epidemiology.” Mol Carcinog. 2012 Jan;51(1):3-13. doi: 10.1002/mc.20785.
Dando et al., “Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells.” Cell Death Dis. 2013 Jun 13;4:e664.
Kanda et al., “Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers” World J Gastroenterol. 2014 Jul 28; 20(28): 9229–9236.
Keane et al., “A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer.” BMJ Open. 2014 Nov 19;4(11)
Kamisawa et al., “Pancreatic cancer.” Lancet. 2016 Jul 2;388(10039):73-85.
Ilic and Ilic, “Epidemiology of pancreatic cancer.” World J Gastroenterol. 2016 Nov 28; 22(44): 9694–9705.
Hidalgo et al., “Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.” Clin Transl Oncol. 2017; 19(6): 667–681.
Yasmin-Karim, et al., “Enhancing the Therapeutic Efficacy of Cancer Treatment With Cannabinoids.” Front Oncol. 2018 Apr 24;8:114.
Ferro et al., “GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.” Oncogene. 2018 Jul 30.
Stoppa-Lyonnet et al., “Familial invasive breast cancers: worse outcome related to BRCA1 mutations.” J Clin Oncol. 2000 Dec 15;18(24):4053-9.
McKallip et al., “Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.” J Immunol. 2005 Mar 15;174(6):3281-9.
Condeelis and Pollard, “Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.” Cell. 2006 Jan 27;124(2):263-6.
Ligresti et al., “Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.” J Pharmacol Exp Ther. 2006 Sep;318(3):1375-87.
Bauer et al., “Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.” Cancer. 2007 May 1;109(9):1721-8.
Dent et al., “Triple-negative breast cancer: clinical features and patterns of recurrence.” Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.
McAllister et al., “Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.” Mol Cancer Ther. 2007 Nov;6(11):2921-7.
Brandes, “N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hermetic effects on DNA synthesis in vitro, amy improve survival in patients with metastatic breast cancer.” Hum Exp Toxicol, 2008 Feb:27(2):143-7.
Payré et al. “Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism.” Mol Cancer Ther. 2008 Dec;7(12):3707-18.
Fredholm et al., “Breast cancer in young women: poor survival despite intensive treatment.” PLoS One. 2009 Nov 11;4(11):e7695.
Parise et al., “Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.” Breast J. 2009 Nov-Dec;15(6):593-602.
Gonzalez-Angulo et al., “Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.” Clin Cancer Res. 2011 Mar 1;17(5):1082-9.
Shrivastava A et al., “Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.” Mol Cancer Ther. 2011 Jul;10(7):1161-72.
McAllister et al., “Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.” Breast Cancer Res Treat. 2011 Aug;129(1):37-47.
Litton et al., “Earlier Age of Onset of BRCA Mutation-Related Cancers in Subsequent Generations.” Cancer. 2012 Jan 15; 118(2): 321–325.
Moja et al., “Trastuzumab containing regimens for early breast cancer.” Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243.
Kanapathy Pillai SK et al., “Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.” BMC Clin Pathol. 2012 Sep 26;12:18.
Lin et al., “Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.” Cancer. 2012 Nov 15;118(22):5463-72.
Yu et al., “Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.” Clin Cancer Res. 2013 May 15;19(10):2723-33.
Scott et al., “Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules.” Anticancer Res. 2013 Oct;33(10):4373-80.
Murase et al., “Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.” Br J Pharmacol. 2014 Oct; 171(19): 4464–4477.
Elbaz et al., “Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti‐tumor mechanisms of Cannabidiol in breast cancer.” Mol Oncol. 2015 Apr; 9(4): 906–919.
Burstein et al., “Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.” J Clin Oncol. 2016 May 10;34(14):1689-701.
Plasilova et al., “Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database.” Medicine (Baltimore). 2016 Aug; 95(35): e4614.
Scott et al., “Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration.” Int J Oncol. 2017 Jul;51(1):369-377.
Siegel et al., “Cancer statistics, 2018.” CA Cancer J Clin. 2018 Jan;68(1):7-30.
Kenyon, Liu, & Dalgleish, “Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol.” Anticancer Res. 2018 Oct;38(10):5831-5835.
Rasheed et al., “Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25.”Oncogene. 1995 Jun 1;10(11):2243-6.
Chang et al., “Patterns of care for adults with newly diagnosed malignant glioma.” JAMA. 2005 Feb 2;293(5):557-64.
Stupp et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.” N Engl J Med. 2005 Mar 10;352(10):987-96.
Bao et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.” Nature. 2006 Dec 7;444(7120):756-60.
Ohgaki and Kleihues, “Genetic Pathways to Primary and Secondary Glioblastoma.” Am J Pathol. 2007 May; 170(5): 1445–1453.
Zhao et al., “Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.” Science. 2009 Apr 10;324(5924):261-5.
Sanson et al., “Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.” J Clin Oncol. 2009 Sep 1;27(25):4150-4.
Weller et al., “Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.” J Clin Oncol. 2009 Dec 1;27(34):5743-50.
Marcu et al., “Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.” Mol Cancer Ther. 2010 Jan;9(1):180-9.
Torres, “A combined preclinical therapy of cannabinoids and temozolomide against glioma.” Mol Cancer Ther. 2011 Jan;10(1):90-103.
Ohgaki and Kleihues, “The definition of primary and secondary glioblastoma.” Clin Cancer Res. 2013 Feb 15;19(4):764-72.
Soroceanu et al., “Id-1 is a Key Transcriptional Regulator of Glioblastoma Aggressiveness and a Novel Therapeutic Target” Cancer Res. 2013 Mar 1; 73(5): 1559–1569.
Solinas et al., “Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect” PLoS One. 2013; 8(10): e76918.
Ellert-Miklaszewska et al., “Cannabinoid signaling in glioma cells.” Adv Exp Med Biol. 2013;986:209-20.
Noorbakhsh et al., “Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis.” J Neurosurg. 2014 Jan;120(1):31-9.
Scott, Dalgleish, & Liu, “The combination of cannabidiol and Δ9-tetrahydrocannabinolenhances the anticancer effects of radiation in an orthotopicmurine glioma model.” Mol Cancer Ther. 2014 Dec;13(12):2955-67
Nabissi et al., “Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner.” Int J Cancer. 2015 Oct 15;137(8):1855-69.
Louis et al, “The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.” Acta Neuropathol. 2016 Jun;131(6):803-20.
Liebelt et al., “Glioma Stem Cells: Signaling, Microenvironment, and Therapy.” Stem Cells Int. 2016.
Chien et al., “Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry.” Front Public Health. 2016 Jul 21;4:151.
Zhao et al., “The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis.” World J Surg Oncol. 2016; 14: 261.
“GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma.” GW Pharmaceuticals, 2017.
Bunse et al., “Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.” Nat Med. 2018 Aug;24(8):1192-1203.
Kiat Tan et al., “Drug Repositioning in Glioblastoma: A Pathway Perspective.” Front Pharmacol. 2018; 9: 218.
Dumitru et al., “Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs.” Front Mol Neurosci. 2018; 11: 159.